193 related articles for article (PubMed ID: 32049866)
21. The role of primary tumor resection in patients with stage IV colorectal cancer with unresectable metastases.
Urvay S; Eren T; Civelek B; Kilickap S; Yetiysigit T; Ozaslan E
J BUON; 2020; 25(2):939-944. PubMed ID: 32521889
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA.
Franchi M; Barni S; Tagliabue G; Ricci P; Mazzucco W; Tumino R; Caputo A; Corrao G;
Oncologist; 2019 Mar; 24(3):358-365. PubMed ID: 30097524
[TBL] [Abstract][Full Text] [Related]
23. Palliative primary tumor resection may not offer survival benefits for patients with unresectable metastatic colorectal neuroendocrine neoplasms, one multicenter retrospective cohort study.
Yu G; Liu S; Wang Z; Liu Q; Ren H; Hu W
BMC Surg; 2024 Mar; 24(1):85. PubMed ID: 38475759
[TBL] [Abstract][Full Text] [Related]
24. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.
Artaç M; Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS
J Gastrointest Cancer; 2019 Jun; 50(2):214-220. PubMed ID: 29302856
[TBL] [Abstract][Full Text] [Related]
25. Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis.
Simillis C; Kalakouti E; Afxentiou T; Kontovounisios C; Smith JJ; Cunningham D; Adamina M; Tekkis PP
World J Surg; 2019 Jul; 43(7):1829-1840. PubMed ID: 30903246
[TBL] [Abstract][Full Text] [Related]
26. Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis.
Zhang RX; Ma WJ; Gu YT; Zhang TQ; Huang ZM; Lu ZH; Gu YK
World J Surg Oncol; 2017 Jul; 15(1):138. PubMed ID: 28750680
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Ghiringhelli F; Bichard D; Limat S; Lorgis V; Vincent J; Borg C; Berthou J; Orry D; Ortega-Deballon P; Lakkis Z; Facy O; Heyd B; Rat P; Nerich V; Ladoire S
Ann Surg Oncol; 2014 May; 21(5):1632-40. PubMed ID: 24419756
[TBL] [Abstract][Full Text] [Related]
28. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.
van der Kruijssen DEW; Elias SG; van de Ven PM; van Rooijen KL; Lam-Boer J'; Mol L; Punt CJA; Sommeijer DW; Tanis PJ; Nielsen JD; Yilmaz MK; Van Riel JMGH; Wasowiz-Kemps DK; Loosveld OJL; van der Schelling GP; de Groot JWB; van Westreenen HL; Jakobsen HL; Fromm AL; Hamberg P; Verseveld M; Jaensch C; Liposits GI; van Duijvendijk P; Hadj JO; van der Hoeven JAB; Trajkovic M; de Wilt JHW; Koopman M;
Ann Oncol; 2024 Jun; ():. PubMed ID: 38852675
[TBL] [Abstract][Full Text] [Related]
29. Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
Rahbari NN; Biondo S; Frago R; Feißt M; Kreisler E; Rossion I; Serrano M; Jäger D; Lehmann M; Sommer F; Dignass A; Bolling C; Vogel I; Bork U; Büchler MW; Folprecht G; Kieser M; Lordick F; Weitz J;
J Clin Oncol; 2024 May; 42(13):1531-1541. PubMed ID: 38412408
[TBL] [Abstract][Full Text] [Related]
30. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
31. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Figueras J; Lopez-Ben S; Alsina M; Soriano J; Hernandez-Yagüe X; Albiol M; Guardeño R; Codina-Barreras A; Queralt B
Clin Transl Oncol; 2013 Jun; 15(6):460-6. PubMed ID: 23143951
[TBL] [Abstract][Full Text] [Related]
32. Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study.
Lu L; Zhuang T; Shao E; Liu Y; He H; Shu Z; Huang Y; Yao Y; Lin S; Lin S; Chen X; Chen X
PLoS One; 2019; 14(9):e0221964. PubMed ID: 31504043
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL; Shi Q; Goey KKH; Meyers J; Heinemann V; Diaz-Rubio E; Aranda E; Falcone A; Green E; de Gramont A; Sargent DJ; Punt CJA; Koopman M
Eur J Cancer; 2018 Mar; 91():99-106. PubMed ID: 29353165
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors predicting survival in incurable stage IV colorectal cancer patients who underwent palliative primary tumor resection. Retrospective cohort study.
Kim MS; Park EJ; Kang J; Min BS; Lee KY; Kim NK; Baik SH
Int J Surg; 2018 Jan; 49():10-15. PubMed ID: 29198632
[TBL] [Abstract][Full Text] [Related]
35. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S
Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714
[TBL] [Abstract][Full Text] [Related]
36. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
38. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.
He WZ; Rong YM; Jiang C; Liao FX; Yin CX; Guo GF; Qiu HJ; Zhang B; Xia LP
Chin J Cancer; 2016 Jun; 35(1):58. PubMed ID: 27357402
[TBL] [Abstract][Full Text] [Related]
39. Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
Bhatti T; Moser M; Tan KT; Chalchal H; Souied O; Le D; Shaw J; Zaidi A; Gill D; Ahmed S
J Gastrointest Cancer; 2022 Jun; 53(2):427-433. PubMed ID: 33779898
[TBL] [Abstract][Full Text] [Related]
40. Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience.
de Mestier L; Neuzillet C; Pozet A; Desot E; Deguelte-Lardière S; Volet J; Karoui M; Kianmanesh R; Bonnetain F; Bouché O
Eur J Surg Oncol; 2014 Jun; 40(6):685-91. PubMed ID: 24630774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
